Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

doi:10.1007/s00280-016-2966-1

. 2016 Feb;77(2):281-8.

doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20.

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

Yohei Funakoshi¹, Yutaka Fujiwara^{1

2}, Naomi Kiyota¹, Toru Mukohara^{1

3}, Takanobu Shimada¹, Masanori Toyoda¹, Yoshinori Imamura¹, Naoko Chayahara¹, Hideo Tomioka¹, Michio Umezu⁴, Naoki Otsuki⁵, Ken-ichi Nibu⁵, Hironobu Minami^{6

7}

Affiliations

¹ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
² Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
³ Cancer Center, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁴ Division of Nephrology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁵ Department of Otorhinolaryngology - Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁶ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hminami@med.kobe-u.ac.jp.
⁷ Cancer Center, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hminami@med.kobe-u.ac.jp.

PMID: 26791871
PMCID: PMC4747994
DOI: 10.1007/s00280-016-2966-1

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

Yohei Funakoshi et al. Cancer Chemother Pharmacol. 2016 Feb.

. 2016 Feb;77(2):281-8.

doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20.

Authors

Affiliations

¹ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
² Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
³ Cancer Center, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁴ Division of Nephrology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁵ Department of Otorhinolaryngology - Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
⁶ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hminami@med.kobe-u.ac.jp.
⁷ Cancer Center, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hminami@med.kobe-u.ac.jp.

PMID: 26791871
PMCID: PMC4747994
DOI: 10.1007/s00280-016-2966-1

Abstract

Purpose: Creatinine clearance (Ccr) is used as a marker of renal function in cancer chemotherapy, but it is not correlated with glomerular filtration rate (GFR) after high-dose cisplatin treatment. In addition to Ccr, measured using 24-h urine collection (24-h Ccr) or Cockcroft-Gault formula (CGF), the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Japanese GFR estimation equation (the Japanese equation) have been recently developed to estimate GFR for predicting renal function. However, these equations remain to be evaluated, particularly in cancer patients treated with cisplatin. Therefore, we investigated the validity of these equations for predicting the GFR in cancer patients treated with cisplatin.

Methods: GFR was measured by inulin clearance (Cin) in 50 cancer patients and compared with GFR estimated by the CKD-EPI equation, the Japanese equation, and Ccr estimated by CGF or measured by 24-h Ccr before the first and third cisplatin-containing chemotherapy cycles (considered pretreatment and posttreatment, respectively).

Results: Before treatment, the CKD-EPI and the Japanese equations estimated GFR with higher accuracy than Ccr. Posttreatment bias values for GFR estimation using the CKD-EPI and the Japanese equations were lower than those for Ccr. The CKD-EPI and the Japanese equations were also more precise than Ccr. However, for patients with low renal function, these equations still overestimated Cin.

Conclusion: The CKD-EPI and the Japanese equations estimated GFR with lower bias and higher precision than Ccr pre- and postcisplatin treatment. This study is registered at UMIN: 000002167.

Keywords: Cancer patients; Cisplatin; Creatinine clearance; Estimated glomerular filtration rate; Inulin clearance.

PubMed Disclaimer

Figures

**Fig. 1**
Relationship between inulin clearance (Cin) and a the Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI) equation, b the Japanese glomerular filtration rate estimation equation (the Japanese equation), c the Cockcroft–Gault formula (CGF), and d creatinine clearance from 24-h urine collection (24-h Ccr). Black lines show the line of identity

See this image and copyright information in PMC

Cited by

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.
Hatta T, Hase T, Hara T, Kimura T, Kojima E, Abe T, Horio Y, Goto Y, Ozawa N, Yogo N, Shibata H, Shimokata T, Oguri T, Yamamoto M, Yanagisawa K, Ando M, Ando Y, Kondo M, Ishii M, Hasegawa Y. Hatta T, et al. Cancer Med. 2023 Aug;12(15):15955-15969. doi: 10.1002/cam4.6235. Epub 2023 Jun 23. Cancer Med. 2023. PMID: 37351560 Free PMC article.
Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate.
Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, Rohrscheib M, Shapiro JI, Tzamaloukas AH. Alaini A, et al. World J Methodol. 2017 Sep 26;7(3):73-92. doi: 10.5662/wjm.v7.i3.73. eCollection 2017 Sep 26. World J Methodol. 2017. PMID: 29026688 Free PMC article. Review.
Estimating kidney function in patients with cancer: A narrative review.
Claudel SE, Gandhi M, Patel AB, Verma A. Claudel SE, et al. Acta Physiol (Oxf). 2023 Jun;238(2):e13977. doi: 10.1111/apha.13977. Epub 2023 Apr 30. Acta Physiol (Oxf). 2023. PMID: 37057998 Free PMC article. Review.
Aligning kidney function assessment in patients with cancer to global practices in internal medicine.
Sandhu G, Adattini J, Gordon EA, O'Neill N, Bagnis C, Chambers P, Martin JH, Flynn A, Ibrahim K, Jardine MJ, Johnson DW, Jones GRD, Karapetis CS, Kelly A, Kichenadasse G, Kliman DS, Liauw W, Lucas C, Mallett AJ, Malyszko J, Michael M, Pollock CA, Roberts DM, Rosner MH, Routledge DJM, Scuderi C, Shingleton J, Shortt J, Siderov J, Sprangers B, Stein BN, Tunnicliffe DJ, Webber K, Ward RL; ADDIKD Working Group. Sandhu G, et al. EClinicalMedicine. 2025 Mar 25;82:103102. doi: 10.1016/j.eclinm.2025.103102. eCollection 2025 Apr. EClinicalMedicine. 2025. PMID: 40290845 Free PMC article. Review.
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M. Muto S, et al. Int J Clin Oncol. 2023 Oct;28(10):1259-1297. doi: 10.1007/s10147-023-02372-4. Epub 2023 Jun 29. Int J Clin Oncol. 2023. PMID: 37382749 Review.

See all "Cited by" articles

References

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(4):1310–1317. - PubMed
1. Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer–an old rivalry renewed. J Natl Cancer Inst. 2007;99(11):828–829. doi: 10.1093/jnci/djk222. - DOI - PubMed
1. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. - DOI - PubMed
1. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901. doi: 10.1517/14656566.4.6.889. - DOI - PubMed
1. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–445. doi: 10.1080/08880010590964381. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Associated data

JPRN/UMIN000002167

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(4):1310–1317. - PubMed

[2] Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(4):1310–1317. - PubMed

[3] Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer–an old rivalry renewed. J Natl Cancer Inst. 2007;99(11):828–829. doi: 10.1093/jnci/djk222. - DOI - PubMed

[4] Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer–an old rivalry renewed. J Natl Cancer Inst. 2007;99(11):828–829. doi: 10.1093/jnci/djk222. - DOI - PubMed

[5] Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. - DOI - PubMed

[6] Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. - DOI - PubMed

[7] Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901. doi: 10.1517/14656566.4.6.889. - DOI - PubMed

[8] Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901. doi: 10.1517/14656566.4.6.889. - DOI - PubMed

[9] Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–445. doi: 10.1080/08880010590964381. - DOI - PubMed

[10] Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–445. doi: 10.1080/08880010590964381. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

Affiliations

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical